January 19, 2009 -- Takeda Pharmaceutical Company Limited today announced that Takeda Global Research & Development Center, Inc., a wholly owned United States subsidiary, received notification from the U.S. FDA that FDA will not be able to complete its review of the febuxostat New Drug Application by the Prescription Drug User Fee Act (PDUFA) date of January 18, 2009.
The details can be read here.
No comments:
Post a Comment